A father’s perspective on raising a son with severe, drug-resistant epilepsy, and how that journey eventually led him to support Neumirna as an early investor

At 11 years old, Emilie experienced her first seizure – a sudden, disorienting moment that marked the beginning of a lifelong condition. What followed was a journey into a world of trial-and-error medication, debilitating side effects and uncertainty that would shape her life through every stage of growing up.

We are excited to announce that Ellen K. Donnelly, Ph.D. has been appointed Chief Executive Officer of Neumirna Therapeutics.

With a proven track record in RNA therapies, Ina will guide Neumirna’s transition into clinical-stage development.

$250,000 in funding to support biomarker research and development of RNA therapy for drug-resistant epilepsy

$200,000 award supports Neumirna’s RNA-based approach to innovation in epilepsy treatment

Neumirna Therapeutics has named Andreas Wallnöfer as an independent member of its Board of Directors.

In honor of World Parkinson’s Day, we are proud to share Lina’s story – an intimate and honest glimpse into the daily reality of living with this complex condition. At Neumirna, we are inspired by stories like Lina’s. They remind us why our work matters and highlight the urgent need for innovative solutions that provide more lasting relief and ease the burden of daily life for people living with Parkinson’s.

Neumirna Therapeutics secures €20M in Series A financing to develop RNA therapies for epilepsy and other neurological disorders

This year’s Nobel Prize in Physiology or Medicine recognizes the discovery of microRNAs. These small RNA molecules are central to Neumirna Therepeutics approach to developing treatments for neurological diseases.

A new review article based on the work led by Clara Mayer and Lluís Riera-Ponsati from Neumirna Therepeutics has been published in Frontiers in Pharmacology.

This substantial funding will be allocated to advance Neumirna's groundbreaking disease-modifying therapy for epilepsy to the clinic, bringing hope to the circa 50 million patients affected by epilepsy worldwide.

Henrik Klitgaard (Co-Founder, PhD) and Stine Norman-Hansen (Senior Scientist, PhD) authored this topical review together with leading pain expert, Prof. Lars Arendt-Nielsen.

Neumirna has been awarded the Nordic Star Award at NLS Days 2023, recognizing the company as the start-up with the highest investment potential.

A new critical review by the Neumirna Therepeutic team has been published in Epilepsia, the leading journal in epilepsy research and clinical care.

This grant from the Innovation Fund Denmark (IFD) will help us in further establishing our drug discovery pipeline, aimed at developing disease-modifying RNA Therapies for Parkinson's Disease at NEUmiRNA, in collaboration with Aalborg University and the Center for RNA Medicine (CRM).

The project, conducted in collaboration with Motac Neuroscience and the Center for RNA Medicine at Aalborg University, aims to accelerate the development of disease-modifying treatments targeting microRNAs in Parkinson’s disease.

A comprehensive review on RNA Therapeutics for the treatment of neurmouscular disorders is out now on the latest issue of RNA Biology.

In 2021, Neumirna was selected and awarded by the US Epilepsy Foundation as being a promising start-up to advance new treatments for people with epilepsy in the EVF global accelerator course for start-up companies.

Janine joined Neumirna from Pfizer, where he served as senior vice president and chief scientific officer of the Rare Disease Research Unit.